![]() |
CZECH MEDICAL ASSOCIATION J. Ev. PURKYNĚ |
Journals - Article | |
![]() |
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
Česky / Czech version | Vnitř. Lék., 50, 2004, No. 11, p. 825 - 829 |
Sibutramin in Obesity Treatment (Multicentric,
Opened, Prospective 12-Month-Long Study) Payer J.1, Hainer V.2, Ondrejka P.3, Kajtor Z.4 1Interné oddelenie, FNsP, Ružinov, Bratislava, Slovenská republika, prednosta prof. MUDr. J. Payer, CSc. 2Endokrinologický ústav, Praha, ředitel doc. MUDr. Vojtěch Hainer, CSc. 3Nemocnica s poliklinikou Ministerstva vnútra SR, Bratislava, Slovenská republika, riaditeľ MUDr. Rudolf Uhliar, CSc. 4Abbott Laboratories Slovakia, s.r.o., Bratislava, Slovenská republika, vedúci divízie kardiológie a obezitológie MUDr. Zoltán Kajtor |
|
Summary: Obesity presents a significant medical and socio-economic problem due its prevalence exceeding
20 % of adult population. Body weight reduction significantly decreases both morbidity from
numerous complications and total mortality. Nonpharmacological measures are the first step in
weight reduction, however an effective pharmacotherapy is also needed in some of the patients.
In a 12-month-long study 50 obese female patients were treated with Sibutramin doses of 10 mg or
15 mg. Sibutramin is a drug with a dual effect: it reduces intake of energy by simultaneous
bringing on a sense of satiety and inhibiting reduction of the energy release which usually accompanies
low energy diets. Medication accompanied with a diet therapy and physical activity led to
a reduction of body weight by 14.9 kg and an important weight loss by 5 % have reached nearly
95 % of patients. The treatment was well tolerated and no significant side effects have been
indicated.
|
|
Order this issue
|
BACK TO CONTENTS | ||
| HOME PAGE | CODE PAGE | CZECH VERSION | |
© 1998 - 2008 CZECH MEDICAL ASSOCIATION J. E. PURKYNĚ |
Created by: NT Servis, s.r.o., hosted by P.E.S. consulting, s.r.o. |
WEBMASTER |